CureVac’s Covid-19 vaccine found to be only 47% effective against disease of any severity

The international Phase IIb/III HERALD study included around 40,000 people from Europe and Latin America. The Company highlighted the ‘unprecedented context’ of the trial, adding there were ‘at least 13 variants’ circulating within the assessed population.